The Importance of Digitization in a Post-COVID World

 

America’s network landscape is quickly evolving thanks to new technologies like 5G. It is redefining the way we do business, learn and connect with each other. But we’re not there yet.

A lot needs to happen, from the budget to build to the software to connect and the spectrum to support all use cases.

On this episode of Nokia Today, host Shelby Skrhak talked with Fuad Siddiqui, Senior Partner and Vice President of Nokia Bell Labs Consulting. There, he leads a team of futurists looking into global macroeconomics, new market models and value-creation strategies. They talked about digitization in a post-COVID world.

In January, Nokia released a whitepaper called “The Big Inversion,” How 5G+ Technologies Will Create New Value for Industries In a Post-Covid World. The paper detailed the need for digitization across all industries, which the COVID-19 pandemic highlighted. The industries that had already invested in digital infrastructure weathered the global crisis significantly better than their counterparts.

“It’s a very opportune time for the industry, as lots of technological advancements are happening,” Siddiqui said. “Lots of technological factors and social factors are all coming together.”

This is why they thought it was a good time to put out the paper. According to Siddiqui, the pandemic massively disrupted our lives and business, but what it also did was usher in an era of accelerated digitization. For companies to prepare themselves for such future challenges, they must achieve a high level of digitization.

“That has not only the potential to enhance industrial growth and profitability but also benefit society and the economy,” Siddiqui said.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More